Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: micdundee2 who wrote (32403)	12/22/2006 4:40:54 PM
From: Bucky Katt	Read Replies (2) \| Respond to of 48461

The complaint was filed the 20th, so that explains the 2 day sell-off after the bump into $5 Chart indicates 2.75 possible. Nothing new, sell the ups & buy the downs. On December 20, 2006, PharmAthene, Inc. ("PharmAthene") filed a complaint (the “Complaint”) against SIGA Technologies, Inc. (“SIGA”) in the Delaware Chancery Court. PharmAthene's complaint alleges that it has the right to license exclusively development and marketing rights for SIGA’s drug candidate, SIGA-246, pursuant to, among other things, the recently terminated merger agreement between the parties. PharmAthene's complaint further alleges that SIGA failed to negotiate the terms of such license in good faith and otherwise failed to grant such license, and it seeks to compel SIGA to enter into such license and pay unspecified damages. SIGA believes that the complaint lacks merit and intends to contest vigorously the alleged claims.